US ‘Drowning in Misinformation’ Under RFK Jr, Autism Advocates Say

Why It Matters

The actions undermine scientific integrity, jeopardize public health, and erode trust among the autistic community and broader public, potentially shaping policy ahead of the midterm elections.

Key Takeaways

• HHS cut autism research funding by $31 million in first year
• All IACC members replaced with advisers holding anti‑vaccine views
• Officials promoted unproven autism treatments like leucovorin and acetaminophen link
• Federal autism committee meeting postponed, then quietly rescheduled
• Advocacy groups demand congressional oversight and possible impeachment

Pulse Analysis

The appointment of Robert F Kennedy Jr. as HHS secretary has intensified a politicized debate over autism, vaccines, and public health messaging. While the administration touts a "science‑first" agenda, its rapid overhaul of the Interagency Autism Coordinating Committee—replacing career scientists with anti‑vaccine advocates—signals a shift toward ideology over evidence. This realignment has already manifested in policy briefs linking prenatal acetaminophen use to autism, a claim that the latest epidemiological studies dispute, and in the promotion of leucovorin, a B‑vitamin approved only for a rare folate deficiency. Such moves risk confusing clinicians and families already navigating a complex care landscape.

Financially, the report highlights a $31 million reduction in federal autism research grants, a cut that narrows the pipeline for innovative therapies and diminishes the United States' competitive edge in neurodevelopmental science. The abrupt postponement and low‑key rescheduling of the IACC’s first meeting further curtails stakeholder engagement, limiting input from researchers, clinicians, and autistic self‑advocates. Meanwhile, the FDA’s pending label change for acetaminophen—warning of potential prenatal exposure effects—adds regulatory weight to a narrative lacking robust support, potentially influencing prescribing habits and consumer behavior.

Politically, the backlash has galvanized disability rights groups, who now call for congressional oversight hearings and even impeachment of the HHS secretary. With midterm elections looming, the administration’s muted communication strategy suggests a tactical retreat from overt controversy, yet the underlying policy positions remain unchanged. This tension underscores a broader clash between evidence‑based health policy and partisan agendas, raising questions about the future of federal support for the autistic community and the integrity of public health institutions.